Literature DB >> 26275482

PACAP as a neuroprotective factor in ischemic neuronal injuries.

Seiji Shioda1, Tomoya Nakamachi2.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 27- or 38-amino acid neuropeptide, which belongs to the vasoactive intestinal polypeptide/glucagon/secretin family. PACAP and its three receptor subtypes are expressed in neural tissues, with PACAP known to exert pleiotropic effects on the nervous system. This review provides an overview of current knowledge regarding the neuroprotective effects, mechanisms of action, and therapeutic potential of PACAP in response to ischemic brain injuries.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  CRMP2; DNA microarray analysis; Ischemia; Neuronal death; PACAP; PACAP receptors

Mesh：

Substances：

Year:  2015        PMID： 26275482     DOI： 10.1016/j.peptides.2015.08.006

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  24 in total

Review 1.  Distribution and Functional Implication of Secretin in Multiple Brain Regions.

Authors:  Ruanna Wang; Billy K C Chow; Li Zhang
Journal:  J Mol Neurosci       Date:  2018-06-07       Impact factor: 3.444

2.  Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.

Authors:  M Feher; B Gaszner; A Tamas; A L Gil-Martinez; E Fernandez-Villalba; M T Herrero; D Reglodi
Journal:  Neurotox Res       Date:  2017-12-11       Impact factor: 3.911

Review 3.  Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides.

Authors:  Li Shan Chiu; Ryan S Anderton; Neville W Knuckey; Bruno P Meloni
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

4.  Early Neurobehavioral Development of Mice Lacking Endogenous PACAP.

Authors:  Jozsef Farkas; Balazs Sandor; Andrea Tamas; Peter Kiss; Hitoshi Hashimoto; Andras D Nagy; Balazs D Fulop; Tamas Juhasz; Sridharan Manavalan; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2017-02-06       Impact factor: 3.444

5.  The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration.

Authors:  A Vaczy; D Reglodi; T Somoskeoy; K Kovacs; E Lokos; E Szabo; A Tamas; T Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

6.  PACAP Is Protective in a Rat Model of Retinopathy of Prematurity.

Authors:  Timea Kvarik; Barbara Mammel; Dora Reglodi; Krisztina Kovacs; Dora Werling; Brigitta Bede; Alexandra Vaczy; Eszter Fabian; Gabor Toth; Peter Kiss; Andrea Tamas; Tibor Ertl; Judit Gyarmati; Tamas Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

Review 7.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

8.  Effect of controlled cortical impact on the passage of pituitary adenylate cyclase activating polypeptide (PACAP) across the blood-brain barrier.

Authors:  Elizabeth M Rhea; Kristin M Bullock; William A Banks
Journal:  Peptides       Date:  2017-10-28       Impact factor: 3.750

9.  Pituitary Adenylate Cyclase-Activating Polypeptide Protects Against Cognitive Impairment Caused by Chronic Cerebral Hypoperfusion.

Authors:  Xiaosu Guo; Ye Tian; Yaping Yang; Shiping Li; Li Guo; Jiong Shi
Journal:  Mol Neurobiol       Date:  2021-05-17       Impact factor: 5.590

Review 10.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.